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Abstract
Background: In the aging population cardiovascular disease (CVD) is highly prevalent. Identification of very old
persons at high risk of recurrent CVD is difficult, since traditional risk markers loose predictive value with age.
Methods: In a population-based sample of 282 85-year old participants with established CVD from the Leiden 85-
plus Study, we studied predictive values of traditional cardiovascular risk markers, a history of major CVD
(myocardial infarction, stroke or arterial surgery), and new cardiovascular biomarkers (estimated glomerular filtration
rate (MDRD), C-reactive protein (CRP), homocysteine and N-terminal pro B-type natriuretic peptide (NT-proBNP))
regarding 5-year risk of recurrent cardiovascular events and mortality (composite endpoint).
Results: During complete 5-year follow-up 157 (56%) participants died. 109 (39%) had a cardiovascular event or
died from cardiovascular causes. Individually related to the composite endpoint were: a history of major CVD (HR 1.5
(95%CI 1.03-2.3)), CRP (HR 1.3 (95%CI 1.03-1.5)), homocysteine (HR 1.4 (95%CI 1.2-2.6)) and NT-proBNP (HR 1.7
(95%CI 1.4-2.1)). A prediction model including all traditional risk markers yielded a C-statistic of 0.59 (95%CI
0.52-0.66). Of all five new markers only addition of NT-proBNP improved the C-statistic (0.67 (95%CI 0.61-0.74,
p=0.023)). The categoryless net reclassification improvement for NT-proBNP was 39% (p=0.001), for a history of
major CVD 27.2% (p=0.03) and for homocysteine 24.7% (p=0.04).
Conclusions: Among very old subjects with established CVD, NT-proBNP was the strongest risk marker for
cardiovascular events and cardiovascular mortality. When estimating risk in secondary prevention in very old age,
use of NT-proBNP should be considered.
Citation: van Peet PG, Drewes YM, de Craen AJM, Gussekloo J, de Ruijter W (2013) NT-proBNP Best Predictor of Cardiovascular Events and
Cardiovascular Mortality in Secondary Prevention in Very Old Age: The Leiden 85-Plus Study. PLoS ONE 8(11): e81400. doi:10.1371/journal.pone.
0081400
Editor: Utpal Sen, University of Louisville, United States of America
Received August 20, 2013; Accepted October 22, 2013; Published November 21, 2013
Copyright: © 2013 van Peet et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The Leiden 85-plus Study was partly funded by an unrestricted grant from the Dutch Ministry of Health, Welfare and Sports. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this
study.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: P.G.van_Peet@lumc.nl
Introduction
In the aging population, cardiovascular disease (CVD) is
highly prevalent and remains a leading cause of death [1,2].
Persons with previous CVD are known to be at high risk of
recurrent CVD [3–7]. However, even though secondary
preventive treatment is effective in very old age [8–11],
treatment at this age is often far from optimal [12–15] and drug
adherence is poor [16]. Identifying patients at highest risk of
recurrent events can help clinicians to select those very old
patients that might benefit most from intensified preventive
lifestyle measures and drug treatment [17].
In secondary prevention, traditional risk markers seem to
have less predictive value [18]. However, data on their actual
value in secondary prevention in very old age are scarce. In
search of improvement of risk stratification, some studies found
additional predictive value by including information on various
degrees of previous CVD [4,19,20]. Many studies have
evaluated the additional predictive value of markers of renal
dysfunction (MDRD, albuminuria or cystatin C), inflammation
(C-reactive protein (CRP)), oxidative stress (homocysteine) or
myocardial wall stress (N-terminal pro B-type natriuretic
peptide (NT-proBNP)), but nearly all in a primary preventive
setting [21–25] and especially aimed at improving prediction in
those with intermediate risk. Although some studies have
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shown incremental predictive value of new biomarkers in
populations with established CVD [20,23,26–31], their
predictive value in a secondary preventive setting in very old
age remains unknown.
We hypothesized that the predictive value of traditional risk
markers in secondary prevention in very old age is limited and
that addition of information on the history of CVD or new
biomarkers (MDRD, CRP, homocysteine and NT-proBNP)
might have incremental value for predicting cardiovascular
events and cardiovascular mortality.
Methods
Study design and participants
The Leiden 85-plus Study is a prospective population-based
study in 85-year-old inhabitants of the city of Leiden in the
Netherlands [32]. In brief, between September 1997 and
September 1999, 705 people from the 1912-14 birth cohort
living in the city of Leiden reached the age of 85 years and
were eligible to participate. No exclusion criteria were used.
From the 705 people who were eligible at age 85, 92 refused
participation and 14 died before enrolment. A total of 599
(87%) people gave informed consent and were enrolled.
At baseline and yearly up to age 90 years participants were
visited at their place of residence to obtain extensive data on
health and functioning; blood samples and an ECG were taken.
Medical history and CVD status were obtained from the
medical records of the participant’s physician. Pharmacists
provided information on all medication used by the participants.
The Medical Ethics Committee of the Leiden University
Medical Center approved the study.
Written informed consent was obtained from all participants.
The protocol adhered to the principles of the Declaration of
Helsinki.
Baseline Assessment of Risk Markers
Traditional risk markers.  Blood pressure was measured on
two occasions with a mean interval of two weeks. Systolic
blood pressure was recorded at the onset of Korotkoff phase I.
The mean of the measured systolic values was used for
analyses.
Serum concentrations of total cholesterol and high-density
lipoprotein were analyzed on fully automated computerised
analyzers (Hitachi 747 and 911; Hitachi, Tokyo, Japan).
Diabetes mellitus was considered present when listed in the
medical records of the participant’s physician, when non-fasting
glucose concentrations were ≥11.0 mmol/l, or when a
participant was taking antidiabetic medication according to the
pharmacist’s records.
All participants were interviewed about present smoking
habits and were considered as smokers if they were a current
smoker of cigarettes, cigars or a pipe.
Nature of the history of cardiovascular disease.  For each
participant, the primary care physician was interviewed about
the CVD history using a standardized questionnaire including
questions on present and past cardiovascular pathologies,
including myocardial infarction (MI), stroke, surgery for arterial
disease, angina, transient ischemic attack (TIA), intermittent
claudication and heart failure. The diagnosis of heart failure
was based on information as obtained from the participant’s
general practitioner or nursing home physician regarding
previous events and prevalent disease at entry of the study at
age 85 years. An ECG was recorded at baseline and
transmitted to the ECG Core laboratory in the Glasgow Royal
Infirmary (Scotland, UK) for automated Minnesota Coding [33].
Presence of a MI on the ECG was defined as the presence of
Minnesota Code 1-1 or 1-2 (excluding 1-2-8).
Major CVD was considered present if there was a history of
MI, stroke, or arterial surgery or if there was a MI on the ECG
at baseline [19]. Minor CVD was considered present if there
was a history of angina, TIA, intermittent claudication or heart
failure.
New risk markers.  MDRD was calculated as follows:
MDRD (ml/min/1,73 m2) = 186 * (serum creatinine (umol/l) / 88,
4)-1154, * age (in years) –0,203 * 0,742(for females).
Plasma concentrations of CRP were measured using a fully
automated Hitachi 747 analyzer (Hitachi, Tokyo, Japan;
detection limit 1 mg/l; coefficient of variation <5%).
Concentrations of homocysteine were measured in plasma
samples with a fluorescence polarisation immunoassay after
reduction to the free form with an IMx analyzer (Abbott, Abbott
Park, IL, USA; coefficient of variation 2.2-2.5%).
NT-proBNP was determined with a chemiluminescent
enzyme immunoassay (CLEIA) procedure (Roche,
Switzerland) and was carried out on a PATHFAST (Mitsubishi
Chemical Medience Corporation, Tokyo.) Detection range was
15 - 30 000 pg/mL and the coefficient of variation was < 5%.
Composite endpoint.  The composite endpoint
‘cardiovascular morbidity and cardiovascular mortality’ was
defined as incident fatal and non-fatal myocardial infarction,
incident fatal and non-fatal stroke or any other cardiovascular
mortality, whichever came first.
Up to age 90 years all incident fatal and non-fatal MIs were
annually registered using data from the primary care physician,
ECGs and death registration forms. Incident MI on the ECG
was defined as the appearance of Minnesota Code 1-1 or 1-2,
or Minnesota Code 1-3 in combination with the first appearance
of Minnesota Code 5-x in the same myocardial area [33]. A
fatal incident MI was categorised by cause of death codes I21-
I23 (ICD 10). Information on incident stroke was collected
annually from the primary care physician up to age 90 years. A
fatal incident stroke was categorised by cause of death codes
I61-I69 (ICD10). All participants were followed for mortality until
age 90 years. Date and cause of death were obtained from
civic and national registries. Causes of death were divided into
cardiovascular causes (ICD-10 codes I00-I99) and non-
cardiovascular causes (all other ICD-10 codes). Assignment of
cause of death was done blinded for baseline and follow-up
study data.
Statistical analysis
Variables that were unevenly distributed were log
transformed.
For all traditional risk markers, a history of major CVD, as
well as, the four new biomarkers, hazard ratios (HRs) and
corresponding 95% confidence intervals (CIs) for
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cardiovascular morbidity and mortality were calculated
univariate and multivariable, using Cox proportional hazards
models, all adjusted for sex. Continuous variables were
entered into the model per SD increase.
We constructed prediction models with the traditional risk
markers (reference model), and with combinations of the
traditional and new risk markers. All biomarkers were entered
in the models as continuous variables. For each participant the
linear predictor score (X-β) was calculated, using Cox
proportional hazard models, all adjusted for sex. Using the
continuous predicted risks from each model, C-statistics and
receiver operating characteristic (ROC) curves with p-values
(level of significance 5%) and 95% CIs were calculated.
We compared the tertiles of predicted risk of the traditional
risk marker model and of new models with the observed 5-year
incidence of the endpoint, using Kaplan-Meier plots adjusted
for competing risks [34] and the log rank test.
Since clinically meaningful risk categories in secondary
prevention are not defined, we also calculated the categoryless
Net Reclassification Index (NRI), comparing new models to the
reference model [35,36].
We estimated the integrated discrimination improvement
(IDI) [37], a quantification of the difference in sensitivities and
‘one minus specificities’ between new models and the
reference model over all possible cut-offs. In addition, we
calculated the relative integrated discrimination improvement
(rIDI) by dividing the integrated discrimination improvement by
the discrimination of the reference model [38].
As a sensitivity analysis regarding the prognostic value of
NT-proBNP we repeated all analyses with exclusion of
participants with a history of heart failure.
To investigate the validity of our results, we repeated the
calculations of C-statistics using cross validated X-beta values
obtained by the ‘jack-knife’ method [39]. This was done for the
prediction models with 1/ all traditional risk markers, 2/ all
traditional risk markers plus NT-proBNP, and 3/ all traditional
risk markers plus all five new markers.
Data analysis was performed using SPSS 20 for Windows
(SPSS Inc., Chicago, IL, USA). Differences in C-statistics were
analysed using Stata/IC 10.0.
Results
Baseline characteristics
Of the 599 participants, all aged 85 years at baseline, 300
(50%) had established CVD. Of these 300 participants, for 282
(94%; 109 males, 173 females) all clinical and laboratory data
were available and they were included in our analyses. Of
these 282 participants 55% had a history of major CVD (32%
with MI or MI on the baseline ECG, 19% with stroke and 13%
with arterial surgery) and 45% had a history of minor CVD
(Table 1). Median NT-proBNP levels were 649 pg/ml (IQR
231-1477) in the subgroup with major CVD, and 405 pg/ml
(174-1196) in the subgroup with minor CVD (p=0.035).
Incidence of composite endpoint
Of the 282 participants, 157 (56%) died during the 5-year
follow-up, of whom 67 (43%) died from cardiovascular causes.
In total 109 (39%) participants experienced the endpoint: 43
(39%) participants experienced a fatal or non-fatal MI, 46
(42%) a fatal or non-fatal stroke, and 20 (18%) died of other
cardiovascular causes.
Univariate and multivariable analyses
Table 2 presents the univariate and multivariable hazard
ratios (HRs) for the endpoint for the traditional risk markers, for
a history of major CVD, and for the four new biomarkers. In
univariate analyses (all adjusted for sex) of the traditional risk
markers, current smoking (HR 1.9 (95% CI 1.2-3.0)) was
associated with a higher risk. A history of major CVD yielded a
HR of 1.5 (95% CI 1.03-2.3). Of the new biomarkers CRP (HR
1.3 (95% CI 1.03-1.5)), homocysteine (HR 1.4 (95% CI
1.1-1.6)) and NT-proBNP (HR 1.7 (95% CI 1.4-2.1)) were
associated with a higher risk, whereas MDRD was not (HR
0.83 (95% CI 0.68-1.01)).
Table 1. Baseline cardiovascular characteristics of
participants with a history of cardiovascular disease at age
85 years (N=282).
 N (%), mean (SD) or median (IQR)a
Traditional risk markers  
 Men 109 (39%)
 Systolic blood pressure, mm Hg 155 (19)
 Total chol, mmol/L 5.7 (1.2)
 HDL chol, mmol/L 1.3 (0.40)
 Diabetes 49 (17%)
 Current smoking 47 (17%)
Nature of cardiovascular disease historyc  
 Myocardial infarction 90 (32%)
 Stroke 52 (19%)
 Arterial surgery 37 (13%)
 Angina 105 (38%)
 Transient ischemic attack 72 (26%)
 Intermittent claudication 34 (12%)
 Heart failure 68 (24%)
 Major CVD 155 (55%)
 Minor CVD 127 (45%)
Cardiovascular medication  
 Aspirin or oral anticoagulant 127 (45%)
 Antihypertensive medicationd 202 (72%)
 Lipid lowering drug 5 (2%)
New risk markers  
 MDRD, ml/min 57 (15)
 CRP, mg/L 5 (2-9)
 HCY, umol/L 14 (11-17)
 NT-proBNP, pg/ml 495 (198-1314)
a. data presented as N (%) for categorical variables, mean (SD) for normally
distributed or median (IQR) for skewed continuous variables,
b. assessed only in participants with MMSE >18,
c. according to treating primary care physician
d. β-blockers, ACE inhibitors, diuretics and/or Calcium channel blockers
doi: 10.1371/journal.pone.0081400.t001
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Figure 1.  ROC curves for cardiovascular morbidity and
mortality.  ROC curves for cardiovascular morbidity and
mortality of three models: traditional risk markers (dotted line),
traditional risk markers plus NT-proBNP (black line, p=0.023),
and traditional risk markers plus all five new markers (a history
of major CVD, MDRD, CRP, homocysteine and NT-proBNP)
(grey line, p=0.0067) (N=282).
doi: 10.1371/journal.pone.0081400.g001
Added individually to a multivariable model with all the
traditional risk markers, the estimates showed no major
change. In a multivariable analysis with all old and new
markers, current smoking (HR 1.8 (95% CI 1.1-2.9)), a history
of major CVD (HR 1.5 (95% CI 1.01-2.3)) and NT-proBNP (HR
1.6 (95% CI 1.3-2.1)), were still independently associated with
an increased risk of cardiovascular morbidity/mortality.
C-statistics
The combination of traditional risk markers had a C-statistic
of 0.59 (95% CI 0.52-0.66) (Table 3). Addition of NT-proBNP
alone to all traditional risk markers increased the C-statistic to
0.67 (95% CI 0.61-0.74) with a p-value for ∆ C-statistic of 0.023
(Figure 1).
Categoryless net reclassification improvement (NRI)
For all different models we calculated the categoryless NRI,
the net percentage of participants that is correctly reclassified
when the new risk marker is added to the reference model with
traditional risk markers (Table 3). Addition of a history of major
CVD reclassified 27.2 % (p=0.03) of the participants correctly.
For CRP this was 16.8 % (p=0.17), for homocysteine 24.7%
(p=0.04) whereas for NT-proBNP it was 39.0 % (p=0.001).
Integrated discrimination improvement (IDI)
The discrimination of the baseline model, based on the
predicted probabilities in those with and without events, was
0.026. The IDI after addition of a history of major CVD, or
MDRD, CRP or homocysteine was not significant (Table 3).
However, addition of NT-proBNP improved the discrimination
Table 2. Univariate (adjusted for sex) and multivariable hazard ratios (HR) for five-year cardiovascular morbidity and
cardiovascular mortalitya, depending on traditional and new risk markers, in participants with a history of cardiovascular
disease (N=282).
 HR (95% confidence interval) for cardiovascular morbidity and mortalitya
 Univariate Multivariable
  All traditional All trad. All trad. All trad. All trad. All trad. All trad.
   + major CVD + MDRD (SD) + CRP (SD) + HCYb (SD) + NT-proBNP (SD) +all new
Traditional risk markers         
 Men 1.4 (0.96-2.0) 1.3 (0.85-2.0) 1.2 (0.79-1.9) 1.4 (0.93-2.2) 1.3 (0.86-2.0) 1.3 (0.85-2.0) 1.3 (0.83-1.9) 1.2 (0.74-1.8)
 RR (∆10 mmHg) 0.95 (0.86-1.1) 0.93 (0.84-1.0) 0.93 (0.84-1.0) 0.93 (0.84-1.0) 0.92 (0.83-1.0) 0.95 (0.85-1.1) 0.96 (0.86-1.1) 0.96 (0.87-1.1)
 Total chol (SD) 1.1 (0.91-1.4) 1.1 (0.92-1.4) 1.1 (0.91-1.4) 1.1 (0.91-1.4) 1.2 (0.94-1.4) 1.1 (0.91-1.4) 1.2 (0.99-1.5) 1.2 (0.98-1.5)
 HDL chol (SD) 1.0 (0.83-1.3) 1.0 (0.82-1.2) 1.0 (0.3-1.3) 1.1 (0.87-1.3) 1.1 (0.87-1.3) 1.1 (0.88-1.3) 1.1 (0.86-1.3) 1.1 (0.92-1.4)
 DM 1.1 (0.66-1.8) 1.1 (0.70-1.9) 1.1 (0.68-1.9) 1.1 (0.67-1.8) 1.1 (0.67-1.8) 1.2 (0.70-1.9) 1.0 (0.62-1.7) 1.0 (0.62-1.7)
 Current smoking 1.9 (1.2-3.0) 1.9 (1.2-3.1) 1.9 (1.2-3.1) 2.0 (1.2-3.2) 2.0 (1.2-3.1) 1.8 (1.1-3.0) 1.8 (1.1-3.0) 1.8 (1.1-2.9)
Major CVDc 1.5 (1.03-2.3)  1.5 (1.001-2.2)     1.5 (1.01-2.3)
New risk markers         
 MDRD (SD) 0.83 (0.68-1.01)   0.81 (0.65-3.7)    1.1 (0.85-1.3)
 CRP (SD) 1.3 (1.03-1.5)    1.3 (1.1-1.6)   1.2 (0.97-1.4)
 HCYb (SD) 1.4 (1.1-1.6)     1.3 (1.1-1.6)  1.2 (0.99-1.6)
 NT-proBNP (SD) 1.7 (1.4-2.1)      1.8 (1.4-2.2) 1.6 (1.3-2.1)
CRP, homocysteine and NT-proBNP are log transformed;a including incident stroke, myocardial infarction or cardiovascular mortality;b HCY: homocysteine;
c. including a history of myocardial infarction, stroke or arterial surgery
doi: 10.1371/journal.pone.0081400.t002
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to 0.067 (p<0.001). Thus for NT-proBNP the relative
discrimination improvement, compared to the discrimination of
the baseline model with traditional risk markers, was 2.55; this
means that the discrimination of the model with addition of NT-
proBNP is more than two and a half times as good as the
discrimination using the model with the traditional risk markers.
Figure 2 presents the Kaplan-Meier curves, adjusted for
competing risks, for 5-year cumulative cardiovascular morbidity
or mortality for the model with traditional risk markers, the
model with NT-proBNP and the model with all five new
markers.
When the analyses were repeated after exclusion of all
participants with a history of heart failure according to
information as obtained from their general practitioner or
nursing home physician at baseline (n=68), results did not
materially change (data not shown).
Cross validation of the model with the traditional risk markers
led to a C-statistic of 0.53 (95%CI 0.46-0.60) for the traditional
risk markers and a C-statistic of 0.64 (95%CI 0.58-0.71) for the
model with addition of NT-proBNP. The difference between
these two cross validated C-statistics was 0.11 (p=0.001). The
cross validated model with addition of all five new markers had
a C-statistic of 0.65 (95%CI 0.58-0.71), difference 0.12
(p=0.001).
Discussion
In this study in very old subjects with established CVD,
traditional risk markers had little predictive value for recurrent
cardiovascular events and cardiovascular mortality. Of all
biomarkers NT-proBNP was by far the strongest, adding
substantial predictive value beyond the traditional risk markers.
Besides NT-proBNP, the nature of the CVD history is also a
relevant risk predictor: participants with a history of MI, stroke
or arterial surgery had a higher recurrence rate than those with
a less severe CVD history. Addition of information about the
CVD history improved risk classification in about one in four
participants. MDRD was not related to the endpoint, CRP was
Table 3. C- statistic, categoryless net reclassification improvement (NRI), integrated discrimination improvement (IDI) and
relative IDI (rIDI) of the different models for prediction of five-year cardiovascular morbidity and mortalitya in participants with
a history of cardiovascular disease (N=282), all compared to a model with traditional risk markersb.
 C-statistic 95% CI ∆ C-statisticc p-value∆c categoryless NRIc (%) p-valueNRIc IDIc p-valueIDIc rIDId
Traditional risk markers 0.59 0.52-0.66        
+ major CVD 0.60 0.53-0.67 0.01 0.59 27.2 0.03 0.012 0.30 0.46
+ MDRD 0.59 0.52 -0.66 0.00 0.74 6.2 0.61 0.0025 0.81 0.095
+ CRP 0.60 0.54 -0.67 0.01 0.65 16.8 0.17 0.008 0.47 0.31
+ Homocysteine 0.62 0.55 -0.69 0.03 0.27 24.7 0.04 0.019 0.13 0.72
+ NT-proBNP 0.67 0.61 -0.74 0.08 0.023 39.0 0.001 0.067 <0.001 2.55
+ all five 0.69 0.62- 0.75 0.10 0.0067 50.8 <0.001 0.089 <0.001 3.39
CRP, homocysteine and NT-proBNP are log transformed;
a. including incident stroke, myocardial infarction or cardiovascular mortality;
b. including sex, systolic blood pressure, total cholesterol, HDL cholesterol, diabetes, current smoking;
c. for comparison against traditional risk markers;
d. for comparison with the discrimination of the model with the traditional risk markers (0.026 in this study)
doi: 10.1371/journal.pone.0081400.t003
Figure 2.  Kaplan-Meier curves, showing cumulative cardiovascular morbidity and mortality.  Kaplan-Meier curves, adjusted
for competing risks, showing cumulative cardiovascular morbidity and mortality for tertiles of risk for three different models:
traditional risk markers only (left graph), traditional risk markers plus NT-proBNP (middle graph), and traditional risk markers plus all
five new markers (a history of major cardiovascular disease, MDRD, CRP, homocysteine and NT-proBNP) (right graph) (N=282).
doi: 10.1371/journal.pone.0081400.g002
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related but failed to show substantial incremental value, and
homocysteine was both related to the endpoint and improved
classification. However, NT-proBNP was the only risk marker
that showed unambiguous improvement of prediction in all
currently advocated methods of evaluation.
In comparison with the literature, in the present study, the
traditional risk markers had little predictive value, with a C-
statistic of 0.59, compared to 0.67 in secondary prevention in
younger age groups [40]; this suggests that, in secondary
prevention in very old age, traditional risk markers indeed loose
predictive value, as they do in primary prevention [41].
Although we already knew that the nature of the CVD history
had prognostic value in very old age [19], we now found it also
has incremental value in prediction models in secondary
prevention.
New risk markers (renal markers (urinary albumin, eGFR,
cystatin C) [31], CRP [30], homocysteine [25,42] and especially
NT-proBNP [23,28,43–45] both individually and in various
combinations have shown incremental predictive value in
secondary prevention [27,46]. However, these studies mainly
included younger participants.
We have now demonstrated that in the oldest old with
established CVD, NT-proBNP is the most potent predictor for
recurrent cardiovascular morbidity and cardiovascular mortality.
In line with the literature [26,28,47] CRP and homocysteine,
although associated with the outcome, show little additional
predictive value when NT-proBNP is also available. As
described earlier in very old age [48], CRP was a weaker
marker in our study than in younger age groups . In the present
study MDRD was not predictive for recurrent cardiovascular
morbidity and cardiovascular mortality. Cystatin C may be a
superior risk marker of kidney function in very old age [49].
The present study has several strengths. The Leiden 85-plus
Study is an observational study of a cohort of very old
inhabitants of the city of Leiden with no exclusion criteria and a
high participation rate. Therefore, our results can be applied to
the general population of the oldest old. Also, the laboratory
tests used are easy to obtain in daily practice and are often
already available to the physician. A limitation is the relative
small sample size of this cohort. We therefore recommend
validation of our findings in a larger cohort. Another limitation is
that, although addition of NT-proBNP was shown to improve
the prediction of cardiovascular morbidity and cardiovascular
mortality, we do not know whether incorporating this new risk
marker in risk stratification in daily practice indeed improves
CVD-free survival. Knowing that participants during the time of
our study were not treated according to current guidelines,
optimizing such treatment with statins and antihypertensive
medication in participants with high NT-proBNP might
considerably improve prognosis.
Regarding clinical implications, we think that physicians may
already improve their risk estimation by using available
knowledge on patients’ CVD history: patients with a history of
major CVD are at increased risk. Likewise, CRP and
homocysteine are related to bad cardiovascular outcomes and
may also be used when available. However, our results call for
incorporation of NT-proBNP in risk estimation in secondary
prevention in very old age as it improves identification of high-
risk patients that will probably benefit most from intensified
secondary preventive treatment and follow-up.
In conclusion, the use of NT-proBNP should be considered
when estimating risk for recurrent cardiovascular events and





• In secondary prevention in very old patients, measurement
of NT-proBNP markedly improves prediction of recurrent
cardiovascular events and cardiovascular mortality.
What Is Relevant?
• NT-proBNP might be used to select older people at the
highest risk for recurrent cardiovascular events who may
benefit most from strict secondary prevention.
Summary
Among very old subjects with established CVD, NT-proBNP
was the strongest risk marker for recurrent cardiovascular
events and cardiovascular mortality and considerably adds
prognostic value on top of traditional risk markers. When
estimating risk in secondary prevention in very old age, use of
NT-proBNP should be considered.
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